Novo Total Other Income Expense Net from 2010 to 2026

NOVA Stock  EUR 32.60  0.80  2.40%   
Novo Nordisk's Total Other Income Expense Net is increasing over the last several years with slightly volatile swings. Total Other Income Expense Net is estimated to finish at about 6.4 B this year. During the period from 2010 to 2026 Novo Nordisk AS Total Other Income Expense Net regressed destribution of quarterly values had coefficient of variationof  8,487 and r-value of  0.40. View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2010-12-31
Previous Quarter
6.1 B
Current Value
6.4 B
Quarterly Volatility
2.8 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Novo Nordisk financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novo Nordisk's main balance sheet or income statement drivers, such as Tax Provision of 16.5 B, Interest Income of 1.3 B or Interest Expense of 4.4 B, as well as many indicators such as . Novo financial statements analysis is a perfect complement when working with Novo Nordisk Valuation or Volatility modules.
  
This module can also supplement various Novo Nordisk Technical models . Check out the analysis of Novo Nordisk Correlation against competitors.
The Total Other Income Expense Net trend for Novo Nordisk AS offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Novo Nordisk is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Novo Nordisk's Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of Novo Nordisk AS over the last few years. It is Novo Nordisk's Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novo Nordisk's overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

Novo Total Other Income Expense Net Regression Statistics

Arithmetic Mean33,120,588
Geometric Mean986,645,932
Coefficient Of Variation8,487
Mean Deviation1,778,640,830
Median(536,000,000)
Standard Deviation2,810,816,483
Sample Variance7900689.3T
Range11.8B
R-Value0.40
Mean Square Error7107828.4T
R-Squared0.16
Significance0.12
Slope220,258,333
Total Sum of Squares126411028.9T

Novo Total Other Income Expense Net History

20266.4 B
20256.1 B
2024-1.1 B
20231.8 B
2022-5.4 B
2021616 M
2020-793 M

About Novo Nordisk Financial Statements

Novo Nordisk stakeholders use historical fundamental indicators, such as Novo Nordisk's Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Although Novo Nordisk investors may analyze each financial statement separately, they are all interrelated. For example, changes in Novo Nordisk's assets and liabilities are reflected in the revenues and expenses on Novo Nordisk's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Novo Nordisk AS. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense Net6.1 B6.4 B

Currently Active Assets on Macroaxis

When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out the analysis of Novo Nordisk Correlation against competitors.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
It's important to distinguish between Novo Nordisk's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Novo Nordisk should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Novo Nordisk's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.